DÄ internationalArchive23/2007Regenerative Medicine with Adult Bone Marrow Derived Stem Cells

Review article

Regenerative Medicine with Adult Bone Marrow Derived Stem Cells

Dtsch Arztebl 2007; 104(23): A-1663

Tögel, F; Lange, C; Zander, A R; Westenfelder, C

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

1. Prockop DJ: Marrow stromal cells as stem cells for nonhematopoietic tissues. Science 1997; 276: 71–4. MEDLINE
2. Ferrari G, Cusella-De Angelis G, Coletta M et al.: Muscle regeneration by bone marrow-derived myogenic progenitors. Science 1998; 279: 1528–30. MEDLINE
3. Bjornson CR, Rietze RL, Reynolds BA et al.: Turning brain into blood: a hematopoietic fate adopted by adult neural stem cells in vivo. Science 1999; 283: 534–7. MEDLINE
4. Petersen BE, Bowen WC, Patrene KD et al.: Bone marrow as a potential source of hepatic oval cells. Science 1999; 284: 1168–70. MEDLINE
5. Wolff E: Vor 50 Jahren: Paul Niehans bringt den Begriff „Zellulartherapie“ in die Öffentlichkeit. Schweizerische Ärztezeitung 2002; 83: 1726–7.
6. Kabelitz D: Nobelpreis für Medizin1990. Dtsch Med Wochenschr 1990; 115: 1927–8. MEDLINE
7. Jacobson LO, Simmons EL, Marks EK, Eldredge JH: Recovery from radiation injury. Science 1951; 113: 510–1. MEDLINE
8. Spangrude GJ, Heimfeld S, Weissman IL: Purification and characterization of mouse hematopoietic stem cells. Science 1988; 241: 58–62. MEDLINE
9. Wagers AJ, Weissman IL: Plasticity of adult stem cells. Cell 2004; 116: 639–48. MEDLINE
10. Friedenstein A: Stromal-hematopoietic interrelationships: Maximov's ideas and modern models. Haematol Blood Transfus 1989; 32: 159–67. MEDLINE
11. Friedenstein AJ, Petrakova KV, Kurolesova AI et al.: Heterotopic of bone marrow. Analysis of precursor cells for osteogenic and hematopoietic tissues. Transplantation 1968; 6: 230–47. MEDLINE
12. Okamoto T, Aoyama T, Nakayama T et al.: Clonal heterogeneity in differentiation potential of immortalized human mesenchymal stem cells. Biochem Biophys Res Commun 2002; 295: 354–61. MEDLINE
13. Makino S, Fukuda K, Miyoshi S et al.: Cardiomyocytes can be generated from marrow stromal cells in vitro. J Clin Invest 1999; 103: 697–705. MEDLINE
14. Verfaillie CM: Multipotent adult progenitor cells: an update. Novartis Found Symp 2005; 265: 55–61; discussion 61–55, 92–57.
15. Stute N, Holtz K, Bubenheim M et al.: Autologous serum for isolation and expansion of human mesenchymal stem cells for clinical use. Exp Hematol 2004; 32: 1212–25. MEDLINE
16. Lange C, Schroeder J, Stute N et al.: High-potential human mesenchymal stem cells. Stem Cells Dev 2005; 14: 70–80. MEDLINE
17. D'Ippolito G, Diabira S, Howard GA et al.: Marrow-isolated adult multilineage inducible (MIAMI) cells, a unique population of postnatal young and old human cells with extensive expansion and differentiation potential. J Cell Sci 2004; 117: 2971–81. MEDLINE
18. Lemischka I: Stem cell dogmas in the genomics era. Rev Clin Exp Hematol 2001; 5: 15–25. MEDLINE
19. Lapidot T, Petit I: Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973–81. MEDLINE
20. Orlic D, Kajstura J, Chimenti S et al.: Mobilized bone marrow cells repair the infarcted heart, improving function and survival. Proc Natl Acad Sci U S A 2001; 98: 10344–9. MEDLINE
21. Fukuhara S, Tomita S, Nakatani T et al.: G-CSF promotes bone marrow cells to migrate into infarcted mice heart, and differentiate into cardiomyocytes. Cell Transplant 2004; 13: 741–8. MEDLINE
22. Kawada H, Takizawa S, Takanashi T et al.: Administration of hematopoietic cytokines in the subacute phase after cerebral infarction is effective for functional recovery facilitating proliferation of intrinsic neural stem/progenitor cells and transition of bone marrow-derived neuronal cells. Circulation 2006; 113: 701–10. MEDLINE
23. Sesti C, Hale SL, Lutzko C et al.: Granulocyte colony-stimulating factor and stem cell factor improve contractile reserve of the infarcted left ventricle independent of restoring muscle mass. J Am Coll Cardiol 2005; 46: 1662–9. MEDLINE
24. Norol F, Merlet P, Isnard R et al.: Influence of mobilized stem cells on myocardial infarct repair in a nonhuman primate model. Blood 2003; 102: 4361–8. MEDLINE
25. Togel F, Isaac J ,Westenfelder C: Hematopoietic stem cell mobilization-associated granulocytosis severely worsens acute renal failure. J Am Soc Nephrol 2004; 15: 1261–7. MEDLINE
e1. Harada M, Qin Y, Takano H, et al.: G-CSF prevents cardiac remodeling after myocardial infarction by activating the Jak-Stat pathway in cardiomyocytes. Nat Med 2005; 11: 305–11. MEDLINE
e.2. Takano H, Qin Y, Hasegawa H, et al.: Effects of G-CSF on left ventricular remodeling and heart failure after acute myocardial infarction. J Mol Med 2006; 84: 185–93. MEDLINE
e3. Schneider A, Kruger C, Steigleder T, et al.: The hematopoietic factor G-CSF is a neuronal ligand that counteracts programmed cell death and drives neurogenesis. J Clin Invest 2005; 115: 2083–98. MEDLINE
e4. Joseph J, Rimawi A, Mehta P, et al.: Safety and effectiveness of granulocyte-colony stimulating factor in mobilizing stem cells and improving cytokine profile in advanced chronic heart failure. Am J Cardiol 2006; 97: 681–4. MEDLINE
e5. Huttmann A, Duhrsen U, Stypmann J, et al.: Granulocyte colony-stimulating factor-induced blood stem cell mobilisation in patients with chronic heart failure. Feasibility, safety and effects on exercise tolerance and cardiac function. Basic Res Cardiol 2006; 101: 78–86. MEDLINE
e6. Wang Y, Tagil K, Ripa RS, et al.: Effect of mobilization of bone marrow stem cells by granulocyte colony stimulating factor on clinical symptoms, left ventricular perfusion and function in patients with severe chronic ischemic heart disease. Int J Cardiol 2005; 100: 477–83. MEDLINE
e7. Ince H, Petzsch M, Kleine HD, et al.: Prevention of left ventricular remodeling with granulocyte colony-stimulating factor after acute myocardial infarction: final 1-year results of the Front-Integrated Revascularization and Stem Cell Liberation in Evolving Acute Myocardial Infarction by Granulocyte Colony-Stimulating Factor (FIRSTLINE-AMI) Trial. Circulation 2005; 112: I73–80. MEDLINE
e8. Ripa RS, Jorgensen E, Wang Y, et al.: Stem cell mobilization induced by subcutaneous granulocyte-colony stimulating factor to improve cardiac regeneration after acute ST-elevation myocardial infarction. Result of the Double-Blind, Randomized, Placebo-Controlled Stem Cells in Myocardial Infarction (STEMMI) Trial. Circulation 2006; 113: 1983–92. MEDLINE
e9. Zohlnhofer D, Ott I, Mehilli J, et al.: Stem cell mobilization by granulocyte colony-stimulating factor in patients with acute myocardial infarction: a randomized controlled trial. JAMA 2006; 295: 1003–10. MEDLINE
e10. Buschmann I, Heil M, Jost M, et al.: Influence of inflammatory cytokines on arteriogenesis. Microcirculation 2003; 10: 371–9. MEDLINE
e11. Seiler C, Pohl T, Wustmann K, et al.: Promotion of collateral growth by granulocyte-macrophage colony-stimulating factor in patients with coronary artery disease: a randomized, double-blind, placebo-controlled study. Circulation 2001; 104: 2012–7. MEDLINE
e12. van Royen N, Schirmer SH, Atasever B, et al.: START Trial: a pilot study on stimulation of arteriogenesis using subcutaneous application of granulocyte-macrophage colony-stimulating factor as a new treatment for peripheral vascular disease. Circulation 2005; 112: 1040–6. MEDLINE
e13. Valgimigli M, Rigolin GM, Cittanti C, et al.: Use of granulocyte-colony stimulating factor during acute myocardial infarction to enhance bone marrow stem cell mobilization in humans: clinical and angiographic safety profile. Eur Heart J 2005; 26: 1838–45. MEDLINE
e14. Kuethe F, Figulla HR, Herzau M, et al.: Treatment with granulocyte colony-stimulating factor for mobilization of bone marrow cells in patients with acute myocardial infarction. Am Heart J 2005; 150: 115. MEDLINE
e15. Shyu WC, Lin SZ, Lee CC, et al.: Granulocyte colony-stimulating factor for acute ischemic stroke: a randomized controlled trial. CMAJ 2006; 174: 927–33. MEDLINE
e16. Grigoropoulos NF ,Mathur A: Stem cells in cardiac repair. Curr Opin Pharmacol 2006; 6: 169–75. MEDLINE
e 17. Lunde K, Solheim S, Aakhus S, et al.: Intracoronary injection of mononuclear bone marrow cells in acute myocardial infarction. N Engl J Med 2006; 355: 1199–209.
e18. Janssens S, Dubois C, Bogaert J, et al.: Autologous bone marrow-derived stem-cell transfer in patients with ST-segment elevation myocardial infarction: double-blind, randomised controlled trial. Lancet 2006; 367: 113–21. MEDLINE
e19. Schachinger V, Tonn T, Dimmeler S, et al.: Bone-marrow-derived progenitor cell therapy in need of proof of concept: design of the REPAIR-AMI trial. Nat Clin Pract Cardiovasc Med 2006; 3 Suppl 1: S23–8. MEDLINE
e20. Meyer GP, Wollert KC, Lotz J, et al.: Intracoronary bone marrow cell transfer after myocardial infarction: eighteen months' follow-up data from the randomized, controlled BOOST (BOne marrOw transfer to enhance ST-elevation infarct regeneration) trial. Circulation 2006; 113: 1287–94. MEDLINE
e21. Tateishi-Yuyama E, Matsubara H, Murohara T, et al.: Therapeutic angiogenesis for patients with limb ischaemia by autologous transplantation of bone-marrow cells: a pilot study and a randomised controlled trial. Lancet 2002; 360: 427–35. MEDLINE
e22. Strauer BE, Brehm M, Zeus T, et al.: Regeneration of human infarcted heart muscle by intracoronary autologous bone marrow cell transplantation in chronic coronary artery disease: the IACT Study. J Am Coll Cardiol 2005; 46: 1651–8. MEDLINE
e23. Bartunek J, Vanderheyden M, Vandekerckhove B, et al.: Intracoronary injection of CD133-positive enriched bone marrow progenitor cells promotes cardiac recovery after recent myocardial infarction: feasibility and safety. Circulation 2005; 112: I178–83. MEDLINE
e24. Erbs S, Linke A, Adams V, et al.: Transplantation of blood-derived progenitor cells after recanalization of chronic coronary artery occlusion: first randomized and placebo-controlled study. Circ Res 2005; 97: 756–62. MEDLINE
e25. Kang HJ, Kim HS, Zhang SY, et al.: Effects of intracoronary infusion of peripheral blood stem-cells mobilised with granulocyte-colony stimulating factor on left ventricular systolic function and restenosis after coronary stenting in myocardial infarction: the MAGIC cell randomised clinical trial. Lancet 2004; 363: 751–6.
e26. Fernandez-Aviles F, San Roman JA, Garcia-Frade J, et al.: Experimental and clinical regenerative capability of human bone marrow cells after myocardial infarction. Circ Res 2004; 95: 742–8. MEDLINE
e27. Stamm C, Westphal B, Kleine HD, et al.: Autologous bone-marrow stem-cell transplantation for myocardial regeneration. Lancet 2003; 361: 45–6. MEDLINE
e28. Tse HF, Kwong YL, Chan JK, et al.: Angiogenesis in ischaemic myocardium by intramyocardial autologous bone marrow mononuclear cell implantation. Lancet 2003; 361: 47–9. MEDLINE
e29. Perin EC, Dohmann HF, Borojevic R, et al.: Improved exercise capacity and ischemia 6 and 12 months after transendocardial injection of autologous bone marrow mononuclear cells for ischemic cardiomyopathy. Circulation 2004; 110: II213–8. MEDLINE
e30. Wollert KC, Meyer GP, Lotz J, et al.: Intracoronary autologous bone-marrow cell transfer after myocardial infarction: the BOOST randomised controlled clinical trial. Lancet 2004; 364: 141–8. MEDLINE
e31. Fuchs S, Kornowski R, Weisz G, et al.: Safety and feasibility of transendocardial autologous bone marrow cell transplantation in patients with advanced heart disease. Am J Cardiol 2006; 97: 823–9. MEDLINE
e32. Assmus B, Schachinger V, Teupe C, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction (TOPCARE-AMI). Circulation 2002; 106: 3009–17. MEDLINE
e33. Schachinger V, Assmus B, Britten MB, et al.: Transplantation of progenitor cells and regeneration enhancement in acute myocardial infarction: final one-year results of the TOPCARE-AMI Trial. J Am Coll Cardiol 2004; 44: 1690–9.
e34. Caplan AI: Review: mesenchymal stem cells: cell-based reconstructive therapy in orthopedics. Tissue Eng 2005; 11: 1198–211. MEDLINE
e35. Caplan AI: Osteogenesis imperfecta, rehabilitation medicine, fundamental research and mesenchymal stem cells. Connect Tissue Res 1995; 31: S9–14. MEDLINE
e36. Caplan AI: Mesenchymal stem cells and gene therapy. Clin Orthop Relat Res 2000: S67–70. MEDLINE
e37. Prockop DJ: Targeting gene therapy for osteogenesis imperfecta. N Engl J Med 2004; 350: 2302–4. MEDLINE
e38. Prockop DJ, Gregory CA, Spees JL: One strategy for cell and gene therapy: harnessing the power of adult stem cells to repair tissues. Proc Natl Acad Sci USA 2003; 100 Suppl 1: 11917–23. MEDLINE
e39. Le Blanc K, Frassoni F, Ball L, et al.: Mesenchymal stem cells for treatment of severe acute and extensive chronic graft-versus-host disease. Blood 2005; 106: a143.
e40. Le Blanc K, Rasmusson I, Sundberg B, et al.: Treatment of severe acute graft-versus-host disease with third party haploidentical mesenchymal stem cells. Lancet 2004; 363: 1439–41. MEDLINE
e41. Chen SL, Fang WW, Qian J, et al.: Improvement of cardiac function after transplantation of autologous bone marrow mesenchymal stem cells in patients with acute myocardial infarction. Chin Med J (Engl) 2004; 117: 1443–8. MEDLINE
e42. Lazarus HM, Koc ON, Devine SM, et al.: Cotransplantation of HLA-identical sibling culture-expanded mesenchymal stem cells and hematopoietic stem cells in hematologic malignancy patients. Biol Blood Marrow Transplant 2005; 11: 389–98. MEDLINE
e43. Horwitz EM: Marrow mesenchymal cell transplantation for genetic disorders of bone. Cytotherapy 2001; 3: 399–401. MEDLINE
e44. Horwitz EM, Gordon PL, Koo WK, et al.: Isolated allogeneic bone marrow-derived mesenchymal cells engraft and stimulate growth in children with osteogenesis imperfecta: Implications for cell therapy of bone. Proc Natl Acad Sci USA 2002; 99: 8932–7. MEDLINE
e45. Horwitz EM, Prockop DJ, Fitzpatrick LA, et al.: Transplantability and therapeutic effects of bone marrow-derived mesenchymal cells in children with osteogenesis imperfecta. Nat Med 1999; 5: 309–13. MEDLINE
e46. Lazarus HM, Haynesworth SE, Gerson SL, et al.: Ex vivo expansion and subsequent infusion of human bone marrow-derived stromal progenitor cells (mesenchymal progenitor cells): implications for therapeutic use. Bone Marrow Transplant 1995; 16: 557–64. MEDLINE
e47. Koc ON, Gerson SL, Cooper BW, et al.: Rapid hematopoietic recovery after coinfusion of autologous-blood stem cells and culture-expanded marrow mesenchymal stem cells in advanced breast cancer patients receiving high-dose chemotherapy. J Clin Oncol 2000; 18: 307–16. MEDLINE
e48. MEDLINE Koc ON, Day J, Nieder M, et al.: Allogeneic mesenchymal stem cell infusion for treatment of metachromatic leukodystrophy (MLD) and Hurler syndrome (MPS-IH). Bone Marrow Transplant 2002; 30: 215–22.
e49. Engelhardt M, Deschler B, Müller C, et al.: Plastizität adulter Stammzellen: Wunschtraum oder Realität? Dtsch Arztebl 2003; 100(49): A 3236–44. VOLLTEXT
e50. Kloner RA: Attempts to recruit stem cells for repair of acute myocardial infarction: A dose of reality. JAMA 2006; 295: 1058–60. MEDLINE
e51. Assmus B, Honold J, Schächinger V, et al.: Transcoronary transplantation of progenitor cells after myocardial infarction. N Engl J Med 2006; 355: 1222–32. MEDLINE
e52. Hofmann M, Wollert KC, Meyer GP, et al.: Monitoring of bone marrow cell homing into the infarcted human myocardium. Circulation 2005; 111: 2198–202. MEDLINE
e53. Rosenzweig A. Cardiac cell therapy–mixed results from mixed cells. N Engl J Med 2006; 355: 1274–7. MEDLINE
e54. Engelmann MG, Theiss HD and Henning-Theiss C et al., Autologous bone marrow stem cell mobilization induced by granulocyte colony-stimulating factor after subacute ST-segment elevation myocardial infarction undergoing late revascularization: final results from the G-CSF-STEMI (Granulocyte Colony-Stimulating Factor ST-Segment Elevation Myocardial Infarction) trial. J Am Coll Cardiol 2006; 48: 1712–21.
e55. Chen S, Liu Z, Tian N, et al: Intracoronary transplantation of autologous bone marrow mesenchymal stem cells for ischemic cardiomyopathy due to isolated chronic occluded left anterior descending artery. J Invasive Cardiol 2006; 18: 552–6. MEDLINE
e51. Mazzini L, Mareschi K, Ferrero I et al.: Autologous mesenchymal stem cells: clinical applications in amyotrophic lateral sclerosis. 2006; 28: 523–6. MEDLINE
e56. Katritsis DG, Sotiropoulou PA, Karvouni E et al: Transcoronary transplantation of autologous mesenchymal stem cells and endothelial progenitors into infarcted human myocardium. Catheter Cardiovasc Interv 2005; 65: 321–9. MEDLINE
e57. Moviglia GA, Fernandes Vina R, Brizuela JA et al.: Combined protocol of cell therapy for chronic spinal cord injury. Report on the electrical and functional recovery of two patients. Cytotherapy 2006; 8: 202–9. MEDLINE
e58. Schächinger V, Erbs S, Elsässer A et al.: Improved clinical outcomes after intracoronary administration of bone-marrow-derived progenitor cells in acute myocardial infarction: final 1-year results of the REPAIR-AMI trial. Europ Heart J 2006; 27: 2775–83. MEDLINE
e59. Bang OY, Lee JS, Lee PH, Lee G. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol 2005; 57: 874–82. MEDLINE
e60. Tögel F, Hu Z, Weiss K, Isaac J, Lange C, Westenfelder C. Administered mesenchymal stem cells protect against ischemic acute renal failure through differentiation independent mechanisms. Am J Physiol Renal Physiol 2005; 289: F31–42. MEDLINE